Effect of Adjuvant Chemotherapy on Stage II Rectal Cancer Outcomes After Preoperative Short-Course Radiotherapy

Clinical Colorectal Cancer

Volumn 15, Issue 4, 2016, Pages 352-359.e1

  Loree, Jonathan M ^a   Kennecke, Hagen F ^a   Renouf, Daniel J ^a   Lim, Howard J ^a   Vickers, Michael M ^b   Speers, Caroline H ^a   Cheung, Winson Y ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Chemoradiotherapy; Colorectal; Locally advanced; Rectal neoplasms; Risk factors

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTINUOUS INFUSION; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; LYMPH NODE; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERINEURAL INVASION; PREOPERATIVE RADIOTHERAPY; RADIATION DOSE; RECTUM CANCER; RECURRENCE FREE SURVIVAL; SHORT COURSE THERAPY; THERAPY EFFECT; TREATMENT DURATION; TUMOR DIFFERENTIATION; ADJUVANT CHEMOTHERAPY; ADJUVANT RADIOTHERAPY; CHEMORADIOTHERAPY; COHORT ANALYSIS; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RECTAL NEOPLASMS; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84976464891     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2016.04.003     Document Type: Article

References (26)

1. 1 Ngan, S.Y., Burmeister, B., Fisher, R.J., et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 30 (2012), 3827–3833.
2. 2 Siegel, R., Burock, S., Wernecke, K., et al. Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society. BMC Cancer, 9, 2009, 50.
3. 3 Bujko, K., Nowacki, M.P., Nasierowska-Guttmejer, A., Michalski, W., Bebenek, M., Kryj, M., Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93 (2006), 1215–1223.
4. 4 Latkauskas, T., Pauzas, H., Gineikiene, I., et al. Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short-course radiotherapy or long-term chemoradiotherapy, both with delayed surgery. Colorectal Dis 14 (2012), 294–298.
5. 5 Petersen, S., Harling, H., Kirkeby, L., Wille-Jørgensen, P., Mocellin, S., Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev, 3, 2012, CD004078.
6. 6 Roh, M.S., Colangelo, L.H., O'Connell, M.J., et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 27 (2009), 5124–5130.
7. 7 Sauer, R., Liersch, T., Merkel, S., et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30 (2012), 1926–1933.
8. 8 Breugom, A.J., Swets, M., Bosset, J.F., et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2045 (2015), 1–8.
9. 9 Breugom, A.J., van Gijn, W., Muller, E.W., et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo) radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol 26 (2015), 696–701.
10. 10 Schmoll, H.J., Van Cutsem, E., Stein, A., et al. ESMO consensus guidelines for management of patients with colon and rectal cancer: a personalized approach to clinical decision making. Ann Oncol 23 (2012), 2479–2516.
11. 11 National Comprehensive Cancer Network. Rectal cancer. NCCN Clinical Practice Guidelines Oncology–Rectal Cancer, 2015. Available at: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed: January 15, 2016.
12. 12 O'Connor, E.S., Greenblatt, D.Y., Loconte, N.K., et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 29 (2011), 3381–3388.
13. 13 Kumar, A., Kennecke, H.F., Renouf, D.J., et al. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer 121 (2015), 527–534.
14. 14 Gill, S., Loprinzi, C.L., Sargent, D.J., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol 22 (2004), 1797–1806.
15. 15 Oken, M.M., Creech, R.H., Tormey, D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 (1982), 649–655.
16. 16 Greene, F., Page, D., Fleming, I., et al. (eds.) American Joint Committee on Cancer Staging Manual, 6th ed., 2002, Springer-Verlag, New York.
17. 17 Benson, A.B., Schrag, D., Somerfield, M.R., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22 (2004), 3408–3419.
18. 18 Kapiteijn, E., Putter, H., Van De Velde, C.J.H., Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in the Netherlands. Br J Surg 89 (2002), 1142–1149.
19. 19 Heald, R., Moran, B., Ryall, R., Sexton, R., MacFarlane, J., Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg 133 (1998), 894–899.
20. 20 Hong, Y.S., Nam, B.H., Kim, K.P., et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 2045 (2014), 1–9.
21. 21 Rödel, C., Graeven, U., Fietkau, R., et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 16 (2015), 979–989.
22. 22 Guillem, J.G., Díaz-González, J.A., Minsky, B.D., et al. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol 26 (2008), 368–373.
23. 23 Pettersson, D., Holm, T., Iversen, H., Blomqvist, L., Glimelius, B., Martling, A., Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. Br J Surg 99 (2012), 577–583.
24. 24 Pettersson, D., Lörinc, E., Holm, T., et al. Tumour regression in the randomized Stockholm III trial of radiotherapy regimens for rectal cancer. Br J Surg 102 (2015), 972–978.
25. 25 Marijnen, C.A., Nagtegaal, I.D., Klein Kranenbarg, E.K., et al. No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 19 (2001), 1976–1984.
26. 26 Edge, S., Byrd, D., Compton, C., Fritz, A., Greene, F., Trotti, A., (eds.) American Joint Committee on Cancer Staging Manual, 7th ed., 2009, Springer-Verlag, New York.